EXPLORING THE DYNAMIC FLUCTUATIONS IN MRNA EXPRESSION LINKED TO THE HISTAMINERGIC SYSTEM IN ENDOMETRIOID ENDOMETRIAL CANCER.

Introduction: Endometrioid endometrial cancer ranks among the most prevalent malignant tumors affecting women in developed nations, with its incidence steadily rising. Over the past decade, its frequency currently reaching 79 cases per 100,000 women in Europe. Histamine, a biogenic amine, exhibits immunomodulatory properties and serves as the primary mediator of severe and acute inflammatory reactions, as well as immediate hypersensitivity reactions. Histamine operates via four distinct receptor subtypes: HRH1, HRH2, HRH3, and HRH4, with its expression documented across various cancer types. Aim: This study aimed to assess alterations in the expression pattern of genes associated with the histaminergic system in boThendometrial tissue samples and whole blood derived from women diagnosed wiThendometrioid endometrial cancer. Material and methods: The study cohort comprised 30 women diagnosed wiThendometrioid endometrial cancer who underwent hysterectomy. Within this group, 15 cases were classified as G1 (well-differentiated), 8 cases as G2 (moderately differentiated), and 7 cases as G3 (poorly differentiated). The control cohort comprised 30 women with no neoplastic changes during routine gynecological examinations. Molecular analysis encompassed microarray analysis of mRnAs associated with the histaminergic system, reverse-transcription quantitative polymerase chain reaction (RT-qPCR), and enzymelinked immunosorbent assay (ELISA). Results: Among 65 mRnAs associated with the histaminergic system, 10 exhibited differentiations between tissue and blood samples obtained from endometrioid endometrial cancer patients compared to the control group (p<0.05). mRnA histamine receptor 1,3 (HRH1, HRH3), and solute carrier family 22 member 3 (SLC23A2) showed differentiation in endometrioid endometrial cancer samples irrespective of their comparison to the control or G group. Conclusions: The findings reveal a complex architecture of the histaminergic system. The identified mRnA targets hold promise for molecularly targeted therapies in the context of endometrioid endometrial cancer. Furthermore, these results may offer insights into assessing the severity of endometrioid endometrial cancer. [ABSTRACT FROM AUTHOR]